CA2049931A1 - Lfa-3 en tant qu'adjuvant vaccinal - Google Patents

Lfa-3 en tant qu'adjuvant vaccinal

Info

Publication number
CA2049931A1
CA2049931A1 CA 2049931 CA2049931A CA2049931A1 CA 2049931 A1 CA2049931 A1 CA 2049931A1 CA 2049931 CA2049931 CA 2049931 CA 2049931 A CA2049931 A CA 2049931A CA 2049931 A1 CA2049931 A1 CA 2049931A1
Authority
CA
Canada
Prior art keywords
lfa
vaccine
hepatitis
adjuvant
immunogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2049931
Other languages
English (en)
Inventor
Barbara P. Wallner
David W. Thomas
Mary A. V. Crimmins
Christopher D. Benjamin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2049931A1 publication Critical patent/CA2049931A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA 2049931 1990-01-24 1991-01-24 Lfa-3 en tant qu'adjuvant vaccinal Abandoned CA2049931A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46914090A 1990-01-24 1990-01-24
US469,140 1990-01-24

Publications (1)

Publication Number Publication Date
CA2049931A1 true CA2049931A1 (fr) 1991-07-25

Family

ID=23862575

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2049931 Abandoned CA2049931A1 (fr) 1990-01-24 1991-01-24 Lfa-3 en tant qu'adjuvant vaccinal

Country Status (5)

Country Link
EP (1) EP0463157A4 (fr)
JP (1) JPH04506666A (fr)
AU (1) AU7300091A (fr)
CA (1) CA2049931A1 (fr)
WO (1) WO1991011194A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223394A (en) * 1989-04-10 1993-06-29 Biogen, Inc. Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence
WO1993006852A2 (fr) * 1991-10-07 1993-04-15 Biogen, Inc. Procede d'amelioration de la tolerance d'allogreffes ou de xenogreffes par administration d'une proteine de liaison de lfa-3 ou de cd2
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
WO1995024217A1 (fr) * 1994-03-08 1995-09-14 Dana-Farber Cancer Institute Procedes de modulation de l'energie des cellules t
ATE513913T1 (de) 2000-05-10 2011-07-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
US7858095B2 (en) 2001-07-24 2010-12-28 Astellas Us Llc Method for treating or preventing sclerotic disorders using CD-2 binding agents
AU2003223527B2 (en) 2002-04-09 2009-01-15 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
CN101124327A (zh) 2003-10-08 2008-02-13 圣诺菲·帕斯图尔公司 经修饰的cea/b7载体
WO2005115436A1 (fr) * 2004-05-07 2005-12-08 Astellas Us Llc Polypeptide lfa-3 soluble destine a traiter de troubles viraux
CN101835488B (zh) 2007-09-04 2018-10-26 美国政府(由卫生和人类服务部、疾病控制和预防中心的部长所代表) 轮状病毒的热灭活
WO2014025198A2 (fr) * 2012-08-09 2014-02-13 주식회사 한독 Mutant de lfa3, protéine de fusion dans laquelle des polypeptides spécifiques d'une cible sont connectés au mutant ou à la région de liaison à cd2 de lfa3, et leur utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
JPH03500659A (ja) * 1988-05-04 1991-02-14 ダナ‐ファーバー・キャンサー・インスチチュート・インコーポレーテッド タンパク質ミセル
JPH03504975A (ja) * 1988-06-14 1991-10-31 セル―エスシーアイ　コーポレイション 異種官能性細胞免疫剤、それを含有するワクチン及びその使用方法

Also Published As

Publication number Publication date
EP0463157A4 (en) 1992-06-03
WO1991011194A1 (fr) 1991-08-08
JPH04506666A (ja) 1992-11-19
EP0463157A1 (fr) 1992-01-02
AU7300091A (en) 1991-08-21

Similar Documents

Publication Publication Date Title
US6004763A (en) Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
Lin et al. Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris.
JP2546544B2 (ja) 免疫強化を促進するための方法と組成物
Kosco et al. In vivo obtained antigen presented by germinal center B cells to T cells in vitro.
US6328972B1 (en) Compositions and methods for inducing cytotoxic T lymphocyte responses by immunization with protein antigens
Kontiainen et al. Suppressor-cell induction in vitro. IV. Target of antigen-specific suppressor factor and its genetic relationships.
AU623106B2 (en) Diagnostic system
US20030180252A1 (en) Methods and compositions for enhancing immune response and for the production of in vitro Mabs
US10808016B2 (en) Peptides and methods for the treatment of diabetes
US20050042272A1 (en) Vesiles derived from t cells, production and uses
CA2049931A1 (fr) Lfa-3 en tant qu'adjuvant vaccinal
Zafiropoulos et al. Induction of antigen-specific isotype switching by in vitro immunization of human naive B lymphocytes
De Becker et al. Immunoglobulin isotype regulation by antigen‐presenting cells in vivo
WO2000000156A2 (fr) Methodes et compositions permettant de moduler les reponses immunitaires (humorales) specifiques a un antigene en ciblant ledit antigene sur des cellules presentatrices de l'antigene en conjonction avec l'administration de ligands anti-cd-40
Burkhart et al. Characterization of T-helper epitopes of the glycoprotein of vesicular stomatitis virus
Gerritsen et al. Clonal dysregulation of the antibody response to tetanus-toxoid after bone marrow transplantation
Jarrett et al. Antibody response and virus survival in cats vaccinated against feline leukaemia
US5045320A (en) Large multivalent immunogen
Gengoux et al. In vivo induction of CD4+ T cell responses by antigens covalently linked to synthetic microspheres does not require adjuvant
EP0734440A1 (fr) Fusions de cellules tumorales et procedes d'utilisation de telles fusions de cellules tumorales
CN113906046A (zh) 具有包含经修饰半胱氨酸的氧化还原酶基序的免疫原性肽
van Essen et al. Role of B cells in maintaining helper T–cell memory
Goeckeritz et al. Enhanced and sustained activation of human B cells by anti‐immunoglobulin conjugated to the EBV glycoprotein gp350
KR20100072211A (ko) 보체 활성 향상을 위한 백신 조성물
CA2307343C (fr) Immunite cellulaire inductible par l'activation de reactions dependantes de th1 et la suppression de reactions dependantes de th2 au moyen de macrophages

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead